Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC. Davey RT Jr, et al. Among authors: polis ma. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14. doi: 10.1073/pnas.96.26.15109. Proc Natl Acad Sci U S A. 1999. PMID: 10611346 Free PMC article. Clinical Trial.
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.
Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I. Anthony KB, et al. Among authors: polis ma. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):125-33. doi: 10.1097/00126334-200306010-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12794543
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. Tavel JA, et al. Among authors: polis ma. J Infect Dis. 2003 Aug 15;188(4):531-6. doi: 10.1086/377285. Epub 2003 Jul 31. J Infect Dis. 2003. PMID: 12898439 Clinical Trial.
Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, Yoder C, Jones E, Chow C, Metcalf JA, Sidorov IA, Dimitrov DS, Polis MA, Kovacs JA. Di Mascio M, et al. Among authors: polis ma. J Virol. 2006 Mar;80(6):2665-74. doi: 10.1128/JVI.80.6.2665-2674.2006. J Virol. 2006. PMID: 16501076 Free PMC article.
Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661.
Davey RT Jr, Dewar RL, Reed GF, Vasudevachari MB, Polis MA, Kovacs JA, Falloon J, Walker RE, Masur H, Haneiwich SE, et al. Davey RT Jr, et al. Among authors: polis ma. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5608-12. doi: 10.1073/pnas.90.12.5608. Proc Natl Acad Sci U S A. 1993. PMID: 8516307 Free PMC article. Clinical Trial.
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC. Davey RT Jr, et al. Among authors: polis ma. J Infect Dis. 1999 Apr;179(4):849-58. doi: 10.1086/314678. J Infect Dis. 1999. PMID: 10068580 Clinical Trial.
177 results